AMGN Related Press Releases
-
Amgen to Present at the Deutsche Bank 38th Annual Healthcare Conference
-
Amgen Announces Voting Results of Annual Meeting of Stockholders
-
RBCC Opens Talks to Acquire Tech Innovators in $142 Billion Drug Delivery Market
-
Amgen To Present At The UBS Global Life Sciences Conference
-
Transgenomic Announces Global Availability of CRC RAScan™ Mutation Detection Test for Use in Patients with Metastatic Colorectal Cancer to Help Identify Appropriate Treatment
-
New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer
-
Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting
-
RBCC Partner n3D Signs U.S. Distribution Agreement
-
Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China
-
Amgen Announces Top-Line Results of Vectibix® (panitumumab) Phase 3 Head-to-Head Study Against Erbitux® (cetuximab) in Metastatic Colorectal Cancer
-
Transgenomic Signs Collaboration Agreement with Amgen for Development of CE-IVD CRC RAScan™ Mutation Detection Tests for Patients with Metastatic Colorectal Cancer
-
World’s Premiere Science Journal Touts Revolutionary Innovations by RBCC Partner Nano3D
-
Four Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California
-
RBCC: Personalized Medicine Poised to Revolutionize Insurance & Pharmaceuticals
-
RBCC Looks Overseas for Potentially Lucrative Licensing Opportunities
-
Amgen's First Quarter 2013 Revenues Increased 5 Percent To $4.2 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $1.96
-
Amgen Announces Webcast of 2013 First Quarter Financial Results
-
RBCC Nears Deal With Leading Genetic Testing Lab
-
Pharmaceutical Companies, Investor Coalition Develop Industry Standard-Setting Principles for Recoupment Policies Covering Major Compliance Failures
Back to AMGN Stock Lookup
